Image Source: CNBC
In a historic move, President Donald Trump signed an executive order on December 18, 2025, to reclassify cannabis from a Schedule I drug to a Schedule III drug under the Controlled Substances Act. This pivotal decision marks one of the most significant shifts in U.S. cannabis policy in over fifty years and is expected to broaden access and usage of cannabis-related products across the nation.
The Impact of Schedule 3 Drugs on Cannabis
The executive order reclassifies cannabis, easing various long-standing restrictions surrounding its use. Previously categorized alongside heroin and LSD as a Schedule I substance, cannabis is now recognized within the Schedule III classificationâone that includes drugs considered to have accepted medical uses, such as ketamine and Tylenol with codeine. This change could revolutionize the landscape for cannabis users and industry participants alike.
Facilitating Research and Healthcare Access
One of the most notable implications of this executive order is the potential for increased research into cannabis and its derivatives. Trump emphasized that this action addresses the needs of patients suffering from chronic pain, incurable diseases, and various medical conditions, including veterans dealing with service-related injuries. The move aims to uplift the quality of life for many Americans reliant on cannabis for relief.
Additionally, the administration is set to launch a Medicare pilot program for CBD products, slated to kick off in April 2026. This initiative will allow certain Medicare-covered seniors to access free, doctor-recommended CBD products that comply with local laws and undergo stringent testing for quality and safety. This unprecedented step signifies the federal acknowledgment of the medicinal potential of cannabis-derived therapies.
Market Reactions and Financial Implications
Following the executive order, the stock market witnessed mixed reactions from cannabis companies. For instance, shares of Tilray Brands surged by approximately 6%, whereas Trulieve and Green Thumb Industries faced declines of about 15% and 5%, respectively. The AdvisorShares Pure US Cannabis ETF, which tracks American cannabis operators, also experienced a drop of over 10% in afternoon trading.
Analysts regard the reclassification as a potential financial lifeline for the cannabis industry. The change permits companies previously hindered by IRS Code Section 280E to deduct standard operating expenses such as salaries and rent for the first time. This newfound financial flexibility could encourage more institutional investment and open banking access previously restricted due to compliance concerns.
Challenges Ahead
Despite the optimistic outlook, industry experts caution that the reclassification does not legalize cannabis in any capacity nor endorse its use as a recreational substance. Trump reiterated that while federal barriers are being lowered, cannabis remains classified as a controlled substance, and further regulatory measures will be necessary to fully integrate it into the healthcare system.
Moreover, competition from large pharmaceutical firms entering the cannabis market is anticipated as they seek to capitalize on federally insured revenues. This new landscape may require existing operators to navigate carefully as major players could pressure smaller entities vying for market share.
Looking Towards the Future
The reclassification of cannabis as a Schedule III drug opens new avenues for research and healthcare applications while providing much-needed relief for many patients. Experts anticipate that this step will promote more in-depth studies into the effects and benefits of CBD and other cannabis-related therapies. As legal barriers reduce, the potential for innovation within the cannabis industry remains vast.
Frequently Asked Questions
What does it mean for cannabis to be classified as a Schedule 3 drug?
Schedule 3 classification indicates that a substance has accepted medical uses and a lower potential for abuse, easing restrictions on its research, sale, and distribution.
Will this change legalize cannabis in the U.S.?
No, the reclassification does not legalize cannabis; it remains a controlled substance under federal law.
How will this affect seniors and access to CBD products?
The reclassification leads to a Medicare pilot program providing certain seniors with access to free CBD products, enhancing their medication options.
What are the market implications of this executive order?
The move is seen as a financial boost for the cannabis industry, allowing companies to deduct standard business expenses and potentially attract more investment.
What are the next steps for cannabis research?
With lowered federal barriers, increased research opportunities into the therapeutic effects of cannabis and its components are expected to develop.
